MX2013013181A - Sulfato de condroitina sulfatado biotecnologico en la posicion 4 o 6 en la misma cadena de polisacarido, y procesamiento para la preparacion del mismo. - Google Patents

Sulfato de condroitina sulfatado biotecnologico en la posicion 4 o 6 en la misma cadena de polisacarido, y procesamiento para la preparacion del mismo.

Info

Publication number
MX2013013181A
MX2013013181A MX2013013181A MX2013013181A MX2013013181A MX 2013013181 A MX2013013181 A MX 2013013181A MX 2013013181 A MX2013013181 A MX 2013013181A MX 2013013181 A MX2013013181 A MX 2013013181A MX 2013013181 A MX2013013181 A MX 2013013181A
Authority
MX
Mexico
Prior art keywords
sulphation
chondroitin sulphate
biotechnological
polysaccharide chain
preparation
Prior art date
Application number
MX2013013181A
Other languages
English (en)
Other versions
MX351660B (es
Inventor
Davide Bianchi
Marco Valetti
Paola Bazza
Niccolo Miraglia
Ermanno Valoti
Original Assignee
Gnosis Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT000829A external-priority patent/ITMI20110829A1/it
Priority claimed from IT000136A external-priority patent/ITMI20120136A1/it
Application filed by Gnosis Spa filed Critical Gnosis Spa
Publication of MX2013013181A publication Critical patent/MX2013013181A/es
Publication of MX351660B publication Critical patent/MX351660B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención presente revela un procedimiento para la producción de sulfato de condroitina con un peso molecular promedio (Mw) de 10-30 kDa por sulfatación química comenzando de un elemento principal de condroitina sin sulfatar, obtenido a su vez por hidrólisis ácida de un polisacárido K4 capsular formado directamente de la cepa E. coli 05:K4:H4, o directamente de una cepa genéticamente modificada de E. coli; la sulfatación del residuo de N-acetil-D-galactosamina en la posición 4 o 6 sucede simultáneamente en la misma cadena de polisacárido, simulando el patrón de sulfatación observado en el sulfato de condroitina natural, a diferencia de (a sulfatación obtenida con los métodos de síntesis descritos a la fecha.
MX2013013181A 2011-05-12 2012-05-10 Sulfato de condroitina sulfatado biotecnológico en la posición 4 o 6 en la misma cadena de polisacárido, y procedimiento para la preparación del mismo. MX351660B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000829A ITMI20110829A1 (it) 2011-05-12 2011-05-12 Condroitin solfato biotecnologico solfatato in posizione 4 o 6 sulla stessa catena polisaccaridica e procedimento per la sua preparazione
IT000136A ITMI20120136A1 (it) 2012-02-02 2012-02-02 Condroitin solfato biotecnologico a basso peso molecolare solfatato in posizione 4 o 6 sulla stessa catena polisaccaridica dotato di attivita' antiinfiammatoria e antiartritica e procedimento per la sua preparazione
PCT/EP2012/058654 WO2012152872A1 (en) 2011-05-12 2012-05-10 "biotechnological sulphated chondroitin sulphate at position 4 or 6 on the same polysaccharide chain, and process for the preparation thereof"

Publications (2)

Publication Number Publication Date
MX2013013181A true MX2013013181A (es) 2013-12-12
MX351660B MX351660B (es) 2017-10-23

Family

ID=46208441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013181A MX351660B (es) 2011-05-12 2012-05-10 Sulfato de condroitina sulfatado biotecnológico en la posición 4 o 6 en la misma cadena de polisacárido, y procedimiento para la preparación del mismo.

Country Status (25)

Country Link
US (2) US20140315854A1 (es)
EP (1) EP2707396B1 (es)
JP (1) JP6205350B2 (es)
KR (1) KR101883910B1 (es)
CN (1) CN103582653B (es)
AU (1) AU2012252415B2 (es)
BR (1) BR112013027389B1 (es)
CA (1) CA2835498C (es)
CY (1) CY1121099T1 (es)
DK (1) DK2707396T3 (es)
EA (1) EA023849B1 (es)
ES (1) ES2705734T3 (es)
GE (1) GEP201606591B (es)
HR (1) HRP20190183T1 (es)
HU (1) HUE042378T2 (es)
IL (1) IL229367A (es)
LT (1) LT2707396T (es)
MX (1) MX351660B (es)
PL (1) PL2707396T3 (es)
PT (1) PT2707396T (es)
RS (1) RS58293B1 (es)
SG (1) SG194898A1 (es)
SI (1) SI2707396T1 (es)
WO (1) WO2012152872A1 (es)
ZA (1) ZA201308458B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130117A1 (it) 2013-01-25 2014-07-26 Gnosis Spa Composizioni comprendenti condroitin solfato, enzimi proteolitici e composti sulfidrilati capaci di migliorare la biodisponibilita' del condroitin solfato
CZ2014451A3 (cs) * 2014-06-30 2016-01-13 Contipro Pharma A.S. Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití
CN111662394B (zh) * 2019-03-05 2022-11-04 中国医学科学院药物研究所 硫酸软骨素多糖半合成制备方法和应用
IT202000013618A1 (it) 2020-06-08 2021-12-08 Vivatis Pharma Gmbh Processo di estrazione di un acido ialuronico da un fungo, un acido ialuronico di origine vegetale e suo uso
IT202000013633A1 (it) 2020-06-08 2021-12-08 Vivatis Pharma Gmbh Processo di estrazione di una condroitina solfato da un fungo, una condroitina solfato di origine vegetale e suo uso

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3405120A (en) * 1966-01-27 1968-10-08 Green Cross Corp Low molecular chondroitin sulfate and method for manufacturing the same
US4704356A (en) * 1984-03-27 1987-11-03 Rush-Presbyterian-St. Luke's Medical Center Method of diagnosing cartilage tissue abnormalities
JPS6144822A (ja) * 1984-08-09 1986-03-04 Seikagaku Kogyo Co Ltd コンドロイチン硫酸含有抗疲労剤
JPH0699485B2 (ja) * 1984-08-14 1994-12-07 生化学工業株式会社 合成コンドロイチン多硫酸の製造法
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
JP4258856B2 (ja) * 1998-03-06 2009-04-30 ニプロ株式会社 抗癌性複合体
ITMI20012200A1 (it) * 2001-10-22 2003-04-22 Ibsa Inst Biochimique Sa Processo per la preparazione di condroitin solfati dal polisaccaride k4 e prodotti ottenuti
JP2003128705A (ja) * 2001-10-29 2003-05-08 Kyowa Technos:Kk 低分子キトサンおよびその製造方法
JP4317350B2 (ja) * 2002-06-12 2009-08-19 生化学工業株式会社 顆粒球マクロファージコロニー刺激因子分泌促進剤
US8455458B2 (en) * 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
JP4567942B2 (ja) * 2002-12-27 2010-10-27 生化学工業株式会社 破骨細胞形成抑制剤
JP4914594B2 (ja) * 2005-09-29 2012-04-11 ユニテックフーズ株式会社 関節痛改善用食品組成物
CN1789287A (zh) * 2005-12-20 2006-06-21 山东大学 一种多硫酸化硫酸软骨素及其制备方法
CN101883794B (zh) * 2007-10-01 2012-11-07 生化学工业株式会社 低分子化硫酸软骨素及其用途
US8394782B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US9109243B2 (en) * 2008-06-04 2015-08-18 Amano Enzyme Usa, Ltd. Microbial-derived chondroitin sulfate
JP5435538B2 (ja) * 2008-09-25 2014-03-05 国立大学法人鳥取大学 コンドロイチン硫酸の低分子化物の製造方法
IT1402871B1 (it) * 2010-11-11 2013-09-27 Ibsa Inst Biochimique Sa Processo per ottenere condroitina solfatata in posizione 4 o 6 dei residui di n-acetil-galattosammina

Also Published As

Publication number Publication date
AU2012252415B2 (en) 2016-11-24
BR112013027389A2 (pt) 2017-01-17
HRP20190183T1 (hr) 2019-03-22
EA201391673A1 (ru) 2014-03-31
CA2835498C (en) 2019-06-25
HUE042378T2 (hu) 2019-06-28
IL229367A (en) 2016-11-30
SI2707396T1 (sl) 2019-02-28
CN103582653B (zh) 2016-08-17
DK2707396T3 (en) 2019-01-28
SG194898A1 (en) 2013-12-30
KR20140034790A (ko) 2014-03-20
JP6205350B2 (ja) 2017-09-27
CA2835498A1 (en) 2012-11-15
JP2014514424A (ja) 2014-06-19
EA023849B1 (ru) 2016-07-29
EP2707396B1 (en) 2018-11-14
RS58293B1 (sr) 2019-03-29
KR101883910B1 (ko) 2018-08-01
US20160108139A1 (en) 2016-04-21
PL2707396T3 (pl) 2019-04-30
CN103582653A (zh) 2014-02-12
AU2012252415A1 (en) 2013-11-28
GEP201606591B (en) 2017-01-10
NZ617564A (en) 2015-06-26
WO2012152872A1 (en) 2012-11-15
CY1121099T1 (el) 2019-12-11
MX351660B (es) 2017-10-23
IL229367A0 (en) 2014-01-30
US20140315854A1 (en) 2014-10-23
LT2707396T (lt) 2019-01-10
ES2705734T3 (es) 2019-03-26
US9908947B2 (en) 2018-03-06
ZA201308458B (en) 2015-02-25
PT2707396T (pt) 2019-01-23
EP2707396A1 (en) 2014-03-19
BR112013027389B1 (pt) 2021-06-01

Similar Documents

Publication Publication Date Title
CY1121099T1 (el) Βιοτεχνολογικα θειωμενη θειικη χονδροϊτινη στη θεση 4 ή 6 στην ιδια αλυσιδα πολυσακχαριτη, και μεθοδος για την παρασκευη αυτης
NZ603762A (en) Production of soluble protein solutions from pulses
WO2011059326A3 (en) Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers
AR064558A1 (es) Proceso para la modificacion de las propiedades termicas y de digestion de almidones de maiz y harinas de maiz
MY148305A (en) Process for production of polysaccharide and/or monosaccharide by hydrolysis of different polysaccharide
TN2013000411A1 (en) Branched 3-phenylpropionic acid derivatives and the use thereof
JP2010215657A5 (es)
BR112015010283A2 (pt) bactéria gram-negativa modificada para a produção de um polissacarídeo, glicoproteína recombinante, método de produzir uma glicoproteína recombinante, e, célula de e. coli modificada
PH12014502444B1 (en) Low-molecular-weight biotechnological chondroitin 6 -sulphate for prevention of osteoarthritis
NZ597898A (en) Biomass hydrolysis
NZ591364A (en) Soluble canola protein isolate production from protein micellar mass
EA201200516A1 (ru) Способ продуцирования молекул, содержащих специализированные гликановые структуры
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
NZ594806A (en) PRODUCTION OF SOLUBLE SOY PROTEIN PRODUCT FROM SOY PROTEIN MICELLAR MASS ("S200Ca")
WO2007087350A3 (en) Methods for regulating gelation of polysaccharide solutions and uses thereof
SG178870A1 (en) Processes for producing silk dope
MX2014007934A (es) Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.
WO2009080743A3 (en) Plants with increased yield (ko nue)
DK2794665T3 (da) Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
BR112014007081A2 (pt) streptococcus dysgalactiae id9103 e método de produção de ácido hialurônico usando o mesmo
MX2009003480A (es) Metodos para mejorar la produccion de anticuerpo.
EP2543681A4 (en) METHOD FOR THE PRODUCTION OF CATIONULATED CELLULOSE AND METHOD FOR THE PRODUCTION OF CATIONIZED HYDROXYALKYL CELLULOSE
GB201020190D0 (en) Glucans
EP4282972A3 (en) Production of branched chain fatty acids and derivatives thereof in recombinant microbial cells
FR2975259B1 (fr) Procede industriel de preparation d'hydrolysats alcalins de proteines vegetales

Legal Events

Date Code Title Description
FG Grant or registration